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Macrophage Mal1 Deficiency Suppresses Atherosclerosis
in Low-Density Lipoprotein Receptor–Null Mice by
Activating Peroxisome Proliferator-Activated
Receptor-–Regulated Genes
Vladimir R. Babaev, Robert P. Runner, Daping Fan, Lei Ding, Youmin Zhang, Huan Tao, Ebru Erbay,
Cem Z. Go¨rgu¨n, Sergio Fazio, Go¨khan S. Hotamisligil, MacRae F. Linton
Objective—The adipocyte/macrophage fatty acid-binding proteins aP2 (FABP4) and Mal1 (FABP5) are intracellular lipid
chaperones that modulate systemic glucose metabolism, insulin sensitivity, and atherosclerosis. Combined deficiency of
aP2 and Mal1 has been shown to reduce the development of atherosclerosis, but the independent role of macrophage
Mal1 expression in atherogenesis remains unclear.
Methods and Results—We transplanted wild-type (WT), Mal1/, or aP2/ bone marrow into low-density lipoprotein
receptor–null (LDLR/) mice and fed them a Western diet for 8 weeks. Mal1/3LDLR/ mice had significantly
reduced (36%) atherosclerosis in the proximal aorta compared with control WT3LDLR/ mice. Interestingly,
peritoneal macrophages isolated from Mal1-deficient mice displayed increased peroxisome proliferator-activated
receptor- (PPAR) activity and upregulation of a PPAR-related cholesterol trafficking gene, CD36. Mal1/
macrophages showed suppression of inflammatory genes, such as COX2 and interleukin 6. Mal1/3LDLR/ mice
had significantly decreased macrophage numbers in the aortic atherosclerotic lesions compared with WT3LDLR/
mice, suggesting that monocyte recruitment may be impaired. Indeed, blood monocytes isolated from Mal1/3LDLR/
mice on a high-fat diet had decreased CC chemokine receptor 2 gene and protein expression levels compared with WT
monocytes.
Conclusion—Taken together, our results demonstrate that Mal1 plays a proatherogenic role by suppressing PPAR
activity, which increases expression of CC chemokine receptor 2 by monocytes, promoting their recruitment to
atherosclerotic lesions. (Arterioscler Thromb Vasc Biol. 2011;31:1283-1290.)
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Fatty acid-binding proteins (FABPs) play important rolesin fatty acid transport, cellular signaling, gene transcrip-
tion, and cytoprotection.1 FABPs belong to a family of 14- to
15-kDa proteins that bind with high affinity to hydrophobic
ligands, such as saturated and unsaturated long-chain fatty
acids, eicosanoids, and other lipids.2 The adipocyte/macro-
phage FABPs aP2 (FABP4) and Mal1 (FABP5) are intracel-
lular lipid chaperones that modulate systemic metabolism of
glucose and lipids, insulin sensitivity, and atherosclerosis.2
We have previously demonstrated that either deficiency of
aP2 or combined deficiency of the aP2 and Mal1 genes
significantly attenuates atherosclerosis in apolipoprotein E
(apoE)/ mice on a normal chow diet or a high-fat diet.3–5
Bone marrow transplantation studies demonstrated that the
antiatherogenic effect of aP2 deficiency is predominantly, if
not entirely, related to its actions in the macrophage and is
independent of the impact of aP2 on insulin sensitivity.2,5
However, the independent role of macrophage Mal1 expres-
sion in atherogenesis has not been studied yet.
Previous reports have shown that macrophage aP2 defi-
ciency significantly enhances the nuclear hormone peroxi-
some proliferator-activated receptor- (PPAR) activity in
macrophages, increasing both CD36-mediated uptake of ox-
idized low-density lipoprotein (OxLDL) and ABCA1-
mediated cholesterol efflux in the cells.6 In addition, aP2/
macrophages have reduced IB kinase activity and nuclear
factor-B (NF-B)–related inflammatory gene expression.6
These aP2-related changes in macrophage cholesterol traf-
ficking and inflammation have a dramatic impact on the
development of atherosclerosis. Macrophages express the aP2
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and Mal1 FABP isoforms at a ratio of approximately 1:1.5
These 2 proteins have 52% amino-acid similarity and bind
various fatty acids and synthetic compounds with similar
selectivity and affinity.7 The high degree of homology in
structure and ligand affinity between aP2 and Mal1 suggests
that Mal1 may have similar, and possibly redundant, roles to
aP2 in macrophage biology and atherogenesis.
Recent studies demonstrated that FABPs act as chaperones,
facilitating transport of fatty acids from the plasma membrane
to different intracellular compartments.2 Mal1 expression
modulates systemic insulin sensitivity in 2 models of obesity
and insulin resistance.2,8 This may induce basal and insulin-
stimulated phosphorylation of Akt in adipose and muscle
tissues specific for aP2//Mal1/ mice.9 Akt is a key
regulator of macrophage survival and inflammatory re-
sponses, and several studies have indicated an important role
for macrophage Akt signaling in atherosclerosis.10,11 How-
ever, the impact of Mal1 expression on macrophage Akt
expression and the development of atherosclerosis has not
been previously examined.
To study the role of macrophage Mal1 in early atheroscle-
rosis, we generated chimeric low-density lipoprotein recep-
tor–null (LDLR/) mice with Mal1-deficient hematopoietic
cells and challenged them with a Western diet for 8 weeks.
Recipient mice reconstituted with Mal1/ marrow had
significantly smaller (36%) atherosclerotic lesions compared
with control mice transplanted with WT marrow. In addition,
Mal1/ macrophages displayed a significant increase in
PPAR activity and affected expression of the PPAR-
regulated gene CD36 and genes involved in inflammation,
including suppression of CC chemokine receptor 2 (CCR2)
levels in monocytes, which likely reduces their recruitment to
atherosclerotic lesions.
Methods
Animal Procedures
The Mal1-deficient mice were developed using homologous recom-
bination in embryonic stem cells, as described,12 and backcrossed 10
or more generations onto C57BL/6 background.13 All recipient
LDLR/ mice and corresponding wild-type (WT) controls were
purchased from the Jackson Laboratory (Bar Harbor, ME). Mice
were maintained in microisolator cages on a rodent chow diet
containing 4.5% fat (PMI 5010, St. Louis, MO) or on a Western-type
diet containing 21% milk fat and 0.15% cholesterol (Teklad, Madi-
son, WI). Animal care and experimental procedures were performed
according to the regulations of Vanderbilt University’s Animal Care
Committee.
Genotyping and Bone Marrow Transplantation
To identify the Mal1 genotype, we generated a set of primers (GAC
GAT ATA AGC GCA GAT GG, AAC TGA GGG GCT GTT TGT
AG and TCG CCT TCT ATC GCC TTC TTG AC) producing a
610-bp band specific for the Mal1 targeted allele and a 435-bp band
specific for the WT allele by polymerase chain reaction (PCR)
analysis. Recipient 8-week-old female LDLR/ mice were lethally
irradiated (9 Gy) from a cesium gamma source and transplanted with
5106 bone marrow cells from female Mal1/, aP2/, or WT
donor mice as described.14
Serum Lipids and Lipoprotein
Distribution Analyses
Mice were fasted for 4 hours, and then serum total cholesterol and
triglycerides were measured by enzymatic methods using reagents
from Raichem (San Diego, CA) and SoftMax Pro5 software
(Molecular Devices). Fast performance liquid chromatography was
performed on a high-performance liquid chromatography system
(model 600, Waters, Milford, MA) using a Superose 6 column
(Pharmacia, Piscataway, NJ).
Analysis of Aortic Lesions
Aortas were flushed through the left ventricle, and cryosections of
the proximal aorta were analyzed using the Imaging System KS 300
(Kontron Electronik GmbH) as described.15
Peritoneal Macrophages: Isolation and Treatment
Thioglycollate-elicited peritoneal macrophages were isolated from
WT and Mal1/ mice. Macrophages were treated with 0.5 mmol/L
palmitic acid complexed to bovine serum albumin (BSA) as de-
scribed,16 with human OxLDL (100 g/mL) or acetylated low-
density lipoprotein (AcLDL, 100 g/mL, Intracel Corp, Rockville,
MD) plus an ACAT inhibitor, Sandoz 58035 (10 g/mL; Sigma) as
described,17 or with PPAR agonist, ciglitazone (Cayman Chemi-
cals) or PPAR antagonist, GW9662 (Sigma).
Modified Low-Density Lipoprotein Uptake
Macrophages were incubated with 3,3-dioctadecylindocarbocyanine-
labeled human AcLDL or OxLDL (Intracel) at 37°C for 2 hours and
analyzed under a fluorescent microscope or by fluorescence-activated
cell sorting (FACS) flow cytometry as described.15
RNA Isolation and Real-Time PCR
Total RNA was isolated from macrophages using a Trizol reagent
(Life Technologies, Inc) and purified by the RNeasy kit (Qiagen,
Valencia, CA). Relative quantitation of the target mRNA was performed
using primers, probes, and the Sequence Detection System (Applied
Biosystems) and normalized with 18S ribosomal RNA as described.18
Blood Monocyte Analyses
Blood was collected from mice in the presence of 5 units of heparin,
and the opaque layer of mononuclear cells was isolated by Histopaque-
1077 (Sigma) gradient. Then, cells were kept in a 6-well plate at 37°C
for 30 minutes and washed with PBS. CCR2 protein expression was
detected by a rabbit monoclonal antibody to CCR2 (Epitomics, Burlin-
game, CA) and analyzed by FACS (Becton Dickinson) as described.15
Western Blotting
Cells were treated with a cell lysis buffer (Cell Signaling Technol-
ogy, Danvers, MA) with a protease (Sigma-Aldrich) and a phospha-
tase inhibitor (Pierce) cocktail. Proteins (20 to 100 g/lane) were
resolved by NuPAGE Bis-Tris electrophoresis (Invitrogen) and
transferred onto polyvinylidene difluoride nitrocellulose membranes
(Amersham Bioscience). Blots were probed with rabbit antibodies to
PPAR (catalog no. ab27649, Abcam, Inc, Cambridge, MA); Akt
and p-Akt (from Cell Signaling Technology); c-Rel, NF-B, p65,
and IB (Santa Cruz Biotechnology); -actin (Abcam); and goat
anti-rabbit horseradish peroxidase–conjugated secondary antibodies
(Upstate Cell Signaling, Lake Placid, NY). Peroxidase enzyme
visualized with ECL Western blotting detection reagents (GE
Healthcare) on x-ray films. To quantify the bands obtained via
Western blot analysis, we used National Institutes of Health ImageJ
software (http://rsb.info.nih.gov/ij/).
Statistical Analysis
The statistical differences in mean serum lipids and aortic lesion
areas between the groups were determined by 1-way ANOVA test
and t test.
Results
Mal1 Deficiency in Hematopoietic Cells Does Not
Affect Serum Lipid Levels but Suppresses
Early Atherosclerosis
To study the impact of macrophage Mal1 expression on early
atherosclerosis, we used bone marrow transplantation to
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generate LDLR/ mice with hematopoietic cells from
Mal1/ mice (n15), aP2/ mice (n15), or control WT
mice (n13). Four weeks posttransplantation, recipient mice
were challenged with a Western diet for 8 weeks. There was
a steady increase in body weight, with no differences between
the groups (Figure 1A). No significant differences were found
in serum total cholesterol and triglyceride levels between the
groups either on chow or Western diet for 4 and 8 weeks
(Table). Similarly, size exclusion chromatography analyses
of plasma lipoproteins revealed no differences between mice
reconstituted with WT, Mal1/, or aP2/ marrow (Figure
1B). However, recipient mice receiving Mal1/ or aP2/
bone marrow cells had significantly reduced size (36% and
21%) of atherosclerotic lesions in the proximal aorta com-
pared with mice transplanted with WT cells (Figure 1C).
Mal1 Deficiency Increases PPAR Activity
in Macrophages
Recent studies have implicated enhanced PPAR activity in
aP2/ macrophages as the mechanism responsible for alter-
ing expression of genes that regulate cholesterol homeostasis
and inflammation resulting in inhibition of atherosclerosis.6
Because Mal1 has many similarities to aP2 in both structure
and function, we hypothesized that the antiatherogenic effects
of Mal1 deficiency may result from a similar mechanism. To
test this hypothesis, we isolated peritoneal macrophages from
WT and Mal1/ mice, and incubated them with Dulbecco’s
modified Eagle’s medium containing 10% lipoprotein-
deficient serum overnight. Then, cells were treated with fresh
medium alone (control) or with a potent PPAR agonist,
ciglitazone, with or without the selective PPAR antagonist
GW9662. Real-time PCR analysis indicated that PPAR acti-
vation increased expression of the PPAR gene significantly
higher in Mal1/ macrophages than in WT cells, and these
effects were completely reversed by addition of the PPAR
antagonist (Figure 2A). Similarly, the ligand treatment signifi-
cantly (1.5-fold) increased expression of the CD36 mRNA in
both WT and Mal1/ macrophages (Figure 2B). There was a
similar trend that was not statistically significant for an increase
in expression of the ABCA1 and ABCG1 genes (data not
shown), which are regulated indirectly by PPAR through
LXR. Interestingly, the expression of the CD36, ABCA1, and
ABCG1 genes was significantly increased in Mal1/ macro-
phages compared with WT cells (Supplemental Figure I, avail-
able online at http://atvb.ahajournals.org) when they were loaded
with OxLDL or free cholesterol by incubating them with
AcLDL together with the ACAT inhibitor Sandoz 58035, as
described.17 These data strongly suggest that the PPAR path-
way is upregulated in Mal1-null macrophages.
Next, WT and Mal1/ macrophages were incubated with
increasing doses of ciglitazone. Then proteins were extracted
from the cells and analyzed by Western blot. The ligand
treatment significantly increased PPAR protein expression
in both types of cells but was always higher in Mal1/
macrophages than WT cells (Figure 2C and 2D). Similarly,
Figure 1. Changes in body weight (A), serum lipoprotein profiles
(B), and atherosclerotic lesion area in the proximal aorta (C) of
LDLR/ mice reconstituted with WT (black circles), Mal1/
(white circles), or aP2/ (gray circles) bone marrow cells. Data
from fast performance liquid chromatography analysis (B) are
represented as the average (n3 per group) percentage of total
cholesterol for each fraction. Fractions 14 to 17 contained very-
low-density lipoprotein (VLDL); fractions 18 to 24 contained IDL/
low-density lipoprotein (LDL); and fractions 25 to 30 contain high-
density lipoprotein (HDL). Note the differences (*P0.05) between
mice reconstituted with WT marrow vs mice transplanted with
Mal1/ or aP2/ marrow determined by 1-way ANOVA.
Table. Total Serum Cholesterol and Triglyceride Levels in
LDLR/ Mice Reconstituted With WT, Mal1/, or aP2/
Bone Marrow
Type of Marrow
Reconstituted
Serum
Lipid Baseline
4-W
Western
Diet
8-W
Western
Diet
WT cells (n13) Cholesterol 2019 47626 59726
Triglycerides 958 19811 20721
Mal1/ cells
(n14)
Cholesterol 2083 43316 58418
Triglycerides 915 19416 22814
aP2/ cells
(n15)
Cholesterol 2025 47215 60126
Triglycerides 975 17712 20912
Values are in mg/dL (meanSEM). The number of recipient mice in each
group is indicated by n. The differences were not statistically significant
between the groups at either time point.
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the ciglitazone treatment significantly (1.5-fold) increased
CD36 protein expression levels in both WT and Mal1/
macrophages (Figure 2E and 2F). Then, to verify the role of
PPAR in mediating the increase in CD36, we made use of
the PPAR antagonist GW9662, which covalently modifies a
cysteine residue of PPAR, resulting in complete loss of the
ligand-binding ability of PPAR.19 Interestingly, treatment of
cells with the PPAR antagonist GW9662 in conjunction
with ciglitazone abolished the increase of CD36 expression in
both types of macrophages (Figure 2E and 2F).
Finally, we examined whether activation of scavenger
receptor CD36, which is directly regulated by PPAR, has an
effect on uptake of modified low-density lipoprotein. WT and
Mal1/ macrophages were incubated with 3,3-
dioctadecylindocarbocyanine-labeled AcLDL and 3,3-
dioctadecylindocarbocyanine-labeled OxLDL for 2 hours and
then analyzed visually and by flow cytometry. Compared with
WT cells, Mal1/ macrophages displayed increased uptake of
OxLDL (Figure 3A). FACS analysis demonstrated that Mal1/
macrophages had increased OxLDL uptake (69% to 125%) but
only slightly increased AcLDL uptake (13% to 26%; Figure 3C).
Taken together, these data indicate that Mal1 deficiency acti-
vates the PPAR pathway in macrophages, enhancing expres-
sion of the PPAR-regulated gene CD36, and results in upregu-
lation of CD36-mediated uptake of OxLDL.
Mal1 Deficiency Increases Akt Phosphorylation
and Suppresses COX2 and Interleukin 6 Gene
Expression in Macrophages
Because FABP expression may change Akt activity in differ-
ent types of cells,9 we compared Mal1/ and WT peritoneal
macrophages in their response to a lipotoxic factor, palmitic
acid (0.5 mmol/L) complexed with BSA, used to induce
endoplasmic reticulum stress-related signaling.16 Mal1/
cells had significantly increased levels of Akt activation
(Figure 4A; p-Akt/-actin ratios were 2.2, 1.6, and 1.7 versus
1.0, 1.4, and 1.2, respectively, in WT cells), a survival factor
that is capable of modulating inflammatory pathways, includ-
ing NF-B. In contrast, the expression levels of Akt and
-actin were not significantly different in these 2 types of
cells (Figure 4A; Akt/-actin ratios were 1.0 to 1.2 and. 1.0
to 1.1, respectively). Similarly, treatment with palmitic acid
(0.5 mmol/L) complexed with BSA resulted in significantly
less IB protein in Mal1/ macrophages compared with
Figure 2. Expression of PPAR () and
CD36 (B) genes and PPAR (C and D)
and CD36 (E and F) protein expression
levels in WT and Mal1/ macrophages
treated with the PPAR agonist ciglita-
zone (A to E) alone or together with the
specific PPAR antagonist GW9662 (A).
A and B, Thioglycollate-elicited WT (f)
and Mal1/ () macrophages were
treated with lipid-free Dulbecco’s modi-
fied Eagle’s medium containing the
PPAR agonist ciglitazone (Cigl,
15 mol/L), alone or together with the
specific PPAR antagonist GW9662
(GW, 10 mol/L), at 37°C for 24 hours.
Then RNA was extracted from the mac-
rophages and analyzed by real-time
PCR. Graphs represent data
(meanSEM) of analysis the same num-
ber (n3) of mice per group (*P0.05
between untreated and treated with the
ciglitazone macrophages of the same
group). C to F, WT and Mal1/ macro-
phages were treated with ciglitazone
(15 mol/L), alone or together with
GW9662 (30 mol/L), for 24 hours.
Extracted proteins (50 g/well) were
resolved and analyzed by Western blot.
The data of PPAR/-actin and CD36/
-actin ratios are presented as average
(meanSEM) of the assay of 3 separate
experiments. *Differences between the
groups with the same dose (D, P0.05)
or between control cells and treated with
ciglitazone macrophages (F, P0.001).
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WT cells (Figure 4B, 0.73, 0.81, and 0.53 versus 1.0, 1.35,
and 1.7, respectively). The levels of other NF-B-related
proteins, such as p-65 and c-Rel, were not significantly
different in these cells (Figure 4B). Interestingly, Mal1/
macrophages had significantly higher levels of basal and
lipopolysaccharide-mediated (50 ng/mL) Akt-1 and c-Jun
gene expression than WT cells (Figure 4C and 4D). In
contrast, lipopolysaccharide induced less COX2 and interleu-
kin 6 (IL6) gene expression in Mal1/ macrophages com-
pared with WT cells (Figure 4E and 4F). These data indicate
that Mal1 deficiency increases Akt activity and suppresses
IB protein, COX2, and IL6 gene expression levels in
macrophages.
Mal1 Deficiency Decreases Macrophage Cell
Numbers in Atherosclerotic Lesions and
Suppresses CCR2 Expression by Blood Monocytes
To test whether macrophage Mal1 deficiency affects cell
density in atherosclerotic lesions, we analyzed the number of
nuclei (stained by 4,6-diamidino-2-phenylindole) in the mac-
rophage (MOMA-2 positive) area of atherosclerotic lesions in
the proximal aorta. Compared with control LDLR/ mice
transplanted with WT marrow (Figure 5A to 5C), LDLR/
mice reconstituted with Mal1/ bone marrow (Figure 5D to
5F) had significantly (36%) lower numbers of macrophages
in the lesion area (Figure 5G). These data suggest that
Mal1/ macrophages undergo decreased recruitment to
atherosclerotic lesions.
Next, we lethally irradiated and transplanted male 10-
week-old LDLR/ mice with Mal1/ (n5) or WT
(n5) marrow. Eight weeks later, recipient mice were fed
with the Western diet for 12 weeks. Blood monocytes were
isolated from the recipient mice, and CCR2 gene and
protein levels were analyzed by real-time PCR and FACS.
Real-time PCR demonstrated that Mal1/ monocytes
expressed significantly lower (64%) levels of levels of
CCR2 mRNA compared with WT cells (Figure 5H). Com-
pared with control WT control monocytes, the Mal1/
monocytes also had suppressed (28%) levels of CCR2 protein
expression as detected by FACS (Figure 5I). Similar sup-
pression of CCR2 gene and protein expression levels was
noted in Mal1//apoE/ monocytes compared with
apoE/ cells (Supplemental Figure II). Taken together,
the results indicate that upregulation of the PPAR path-
way in Mal1/ mice suppresses CCR2 expression in
blood monocytes, and this likely affects their recruitment
to atherosclerotic lesions.
Discussion
The adipocyte/macrophage FABPs aP2 and Mal1 link fea-
tures of the metabolic syndrome, including insulin resistance
Figure 3. Visualization (A) and quantified uptake of human 3,3-
dioctadecylindocarbocyanine (DiI)-OxLDL (B) or DiI-AcLDL (C)
by macrophages from WT (f) and Mal1/ () mice. A, Perito-
neal macrophages were incubated with human DiI-OxLDL (10
g/mL) or DiI-AcLDL (10 g/mL) for 2 hours and examined
under the microscope (Olympus BX-40) (magnification 20;
inset magnification 60). B and C, Peritoneal macrophages were
incubated with the indicated doses of human DiI-OxLDL or DiI-
AcLDL for 1 hour and analyzed by FACS.
Figure 4. Treatment with palmitic acid complexed with BSA
(A and B) or lipopolysaccharide (C to F) significantly increased
activity of Akt and slightly suppressed NF-B-related protein
and genes in Mal1-deficient macrophages. A and B, Macro-
phages were incubated with medium alone or with PA-BSA
(0.5 mmol/L) for 3 and 6 hours. Extracted proteins were
resolved (100 g/well) and analyzed by Western blot using anti-
bodies to Akt, p-Akt, or -actin (A), or extracted proteins (20
g/well) were analyzed by Western blot using antibodies to
p-65, c-Rel, IB, or -actin (B). C to F, Peritoneal macro-
phages from WT (F) and Mal1/ (E) mice were treated with
lipopolysaccharide (50 ng/mL) for the indicated time periods,
and the expression of the Akt-1 (C), c-Jun (D), COX2 (E), and
IL6 (F) genes was analyzed by real-time PCR.
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and atherosclerosis.2 Studies with aP2/ or aP2//Mal1/
mice have shown that the elimination of these proteins in total
body or exclusively in hematopoietic cells significantly sup-
presses atherosclerotic lesion formation in apoE/ mice.3–5
Remarkably, aP2 and Mal1 have additive effects with regard
to insulin sensitivity, as aP2/ mice show improved insulin
sensitivity only in the setting of dietary or genetic obesity,
whereas aP2//Mal1/ mice show improved insulin sen-
sitivity on the apoE-deficient background even when lean and
on a normal chow diet.4,5,13 Expression of aP2 and Mal1 by
both adipocytes and macrophages contributes to insulin
resistance.20 However, macrophage aP2 expression promotes
atherosclerosis independently of its impact on insulin sensi-
tivity.3 Because both proteins, aP2 and Mal1, share a high
degree of homology and are expressed by macrophages in
similar proportions,5 we examined the hypothesis that mac-
rophage Mal1 expression influences the development of
atherosclerosis. Here we demonstrate that Mal1 deficiency in
hematopoietic cells significantly inhibits (36%) early athero-
sclerotic lesion formation in LDLR/ mice compared with
control mice reconstituted with WT bone marrow. This effect
is not mediated by differences in serum lipids levels or
lipoprotein distributions.
Previous studies have shown that macrophage aP2 defi-
ciency significantly enhances PPAR activity and suppresses
atherosclerosis formation.6 Therefore, to examine mecha-
nisms underlying the impact of macrophage Mal1 expression
on atherogenesis, we analyzed PPAR gene and protein
expression levels in peritoneal macrophages isolated from
Mal1/ and WT mice. We demonstrated that treatment with
the PPAR agonist ciglitazone increased PPAR gene and
protein expression more in Mal1/ macrophages than in WT
cells, and the effect on PPAR gene expression was reversed
by the addition of a PPAR antagonist (Figure 2A). In
addition, we showed in a dose-response study with ciglita-
zone that PPAR protein expression increased to a greater
extent in Mal1/ macrophages than in WT cells (Figure 2C
and 2D). Our results suggest an interesting possibility that the
promoter of the PPAR gene may contain functional PPAR-
response element (PPRE) sites. Interestingly, a gene database
search of the mouse and human PPAR gene promoters
revealed 3 potential PPRE sites. The site with the highest
score (AGGGCAAAGGCCT) is 100% conserved between
human and mouse, has 10 of 13 (76.9%) identity with the
consensus PPRE sequence, and reveals high similarity with
known functional PPREs in PPAR target genes. (Supple-
mental Figure III). We also demonstrated that expression of
CD36, which is directly regulated by PPAR, was increased
to a greater extent in Mal1/ macrophages than in WT cells
(Figure 3B), and the ciglitazone-related increase in CD36
protein expression was abolished by the PPAR antagonist
GW9662 (Figure 2E and 2F). There was also a trend for an
increase in expression of ABCA1 and ABCG1 gene expres-
sion in ciglitazone-treated Mal1/ macrophages, but it was
not statistically significant (data not shown). It is important to
note that PPAR regulates ABCA1 through LXR, and our
failure to see a significant increase in ABCA1 may be due to
the conditions of the experiment in that the cells were not
loaded with cholesterol. Indeed, Mal1/ macrophages
showed increased expression of CD36, ABCA1, and ABCG1
in response to OxLDL and free cholesterol loading (Supple-
mental Figure I). These findings are consistent with earlier
studies reporting that FABPs bind PPAR ligands and that
FABP overexpression inhibits lipid-mediated signaling to the
PPARs.21 A similar PPAR-active phenotype has been de-
scribed in aP2/ macrophages, and it was associated with an
antiinflammatory status.6 Previous studies have demonstrated
that activation of the PPAR-LXR pathway reciprocally
regulates inflammation and lipid metabolism,22 stimulating
genes involved in cholesterol homeostasis23 and antagonizing
Figure 5. Mal1 deficiency decreased the
number of nuclei in the MOMA-2 area
of atherosclerotic lesions (A to G) and
suppressed CCR2 gene (H) and protein
(I) expression levels in blood monocytes.
A to F, Serial sections from the proximal
aorta of LDLR/ mice reconstituted
with WT (A to C) and Mal1/ (D to F)
marrow and fed the Western diet for 12
weeks. Sections were stained with anti-
bodies to the mouse macrophage
MOMA-2 (A and D) and the nuclear stain
4,6-diamidino-2-phenylindole (B and E).
After merging of the images, the number
of nuclei was analyzed in MOMA-2-
positive area. Note number of nuclei per
standard lesion area (G; meanSEM;
*P0.05 between mice with WT and
Mal1/ marrow). G to I, Blood mono-
cytes were isolated from WT3LDLR/
(f) and Mal1/3
LDLR/() mice on the Western diet.
CCR2 gene (H) and protein (I) expression
levels were analyzed by real-time PCR
and FACS. Graphs represent data
(MeanSEM) analysis of the same num-
ber (n3) mice per group (*P0.05
between WT and Mal1/ cells).
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genes encoding inflammatory proteins.8 Recent studies have
suggested that free cholesterol accumulation may induce a
proinflammatory phenotype in macrophages.24 Indeed, the
increased cellular free cholesterol and lipid raft contents in
ABCA1/ macrophages enhance expression of proinflam-
matory cytokines and activation of the NF-B pathway.25
Taken together, these data indicate that Mal1 deficiency
activates the PPAR pathway in macrophages, protecting
them against proinflammatory and proatherogenic changes.
We also noted that Mal1 deficiency significantly increased
basal and stimulated Akt activity in macrophages. Interest-
ingly, a similar increase of basal and insulin-stimulated
phosphorylation of Akt has been noted in adipose and muscle
tissues of aP2//Mal1/ mice.9 The Akt activation is
higher in the presence of shorter chain (12:0 and 14:0) fatty
acids and strongly inhibited in the presence of longer chain
(16:0 and 18:0) fatty acids.9 Akt signaling promotes cell
survival but also modulates inflammatory responses and
stimulates transport and metabolism of glucose and amino
acids.26 It is important to note that macrophages constitutively
express p-Akt, and inhibition of the pathway significantly
accelerates their apoptosis.11 Consistent with these data, Akt1-
null macrophages are more susceptible to apoptotic stimuli.27
Macrophage aP2 deficiency has been shown to reduce the
activity of IB, which may, at least in part, underlie the
alterations in cytokine expression.6 Similarly, we found that
Mal1 deficiency suppressed COX2, IL6 mRNA, and IB
protein expression in macrophages, although to a lesser
degree than is seen in aP2/ macrophages.6 Next, we
demonstrated that LDLR/ mice reconstituted with Mal1/
bone marrow had decreased numbers of macrophages in their
atherosclerotic lesions compared with control mice trans-
planted with WT bone marrow (Figure 5A to 5G). This
strongly supports the hypothesis that the recruitment of
Mal1/ monocytes to atherosclerotic lesions may be im-
paired, leading to diminished cell numbers in the atheroscle-
rotic lesions. CCR2 is known as a receptor for monocyte
chemoattractant protein 1, which plays pivotal roles in
immune responses and atherosclerosis.28 CCR2 is necessary
for efficient monocyte recruitment from the blood to inflamed
tissue and to atherosclerotic lesions.28 A recent study has
identified PPAR as a critical signaling molecule in deter-
mining macrophage phenotype in vitro, and treatment with a
PPAR agonist enhances the antiinflammatory properties of
macrophages.29 In this regard, PPAR activation by OxLDL
inhibits CCR2 expression in human and mouse monocytes.30
In contrast, macrophage-specific deficiency in PPAR sig-
nificantly accelerates CCR2 expression and atherosclerosis in
LDLR/ mice.15 These findings suggest the hypothesis that
reduced expression of CCR2 by Mal1/ monocytes may
contribute to the reduction in atherosclerosis in the Mal1/3
LDLR/ mice. We did not see an impact of monocyte
chemoattractant protein 1 on macrophage migration in an in
vitro migration assay comparing unstimulated Mal1/and
WT peritoneal macrophages (data not shown). However,
these results do not rule out an important role for reduced
CCR2 expression by Mal1/ monocytes in reducing recruit-
ment to atherosclerotic lesions in vivo. We provide evidence
from Mal1/3LDLR/ mice fed a high-fat diet that
Mal1/ monocyte CCR2 gene and protein expression levels
are reduced in vivo compared with WT cells from control
Mal1/3LDLR/ mice. The relevance of this finding is
supported by our data showing that monocyte deficiency of
Mal1/ reduced CCR2 expression in vivo in a second
genetic model of atherosclerosis, apoE/ mice (Supplemen-
tal Figure II). Although the impact of CCR2 expression on
atherogenesis is not limited to its role in recruitment,31 we
believe that our findings of reduced expression of CCR2 in
Mal1-deficient monocytes, coupled with the in vivo evidence
that the atherosclerotic lesions of Mal1/3LDLR/ mice
have reduced numbers of macrophages, support the hypothesis
that reduced CCR2 expression by Mal1 monocytes contributes
to the reduced atherosclerosis in the Mal1/3LDLR/ mice,
likely because of an impact on recruitment. Together, these data
show that Mal1 expression regulates inflammatory activity in
macrophages and likely affects monocyte recruitment to athero-
sclerotic lesions.
In conclusion, our results demonstrate that macrophage
Mal1 plays an important role in early atherosclerosis. As a
key regulator of PPAR activity and inflammatory responses
in macrophages, Mal1 modulates monocyte recruitment and
the development of atherosclerotic lesions. These findings
support macrophage Mal1 as a potential therapeutic target for
the prevention of atherosclerosis. The potential relevance
of these findings is supported by previous studies demonstrat-
ing that a small-molecule inhibitor of aP2 is able to retard the
development of diabetes and atherosclerosis in murine models.32
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Supplement Data
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Figure I. Expression of PPARγ-related genes in WT and Mal1-/- peritoneal macrophages treated 
with AcLDL or OxLDL for 48 hours.
Thioglycollate-elicited macrophages were  isolated from WT and Mal1-/- mice and loaded with 
OxLDL (100mg/ml) or free cholesterol by incubating them with AcLDL (100mg/ml) plus an ACAT
inhibitor, Sandoz 58035 (10mg/ml), for 24 hours. Total RNA was extracted from cells and 
analyzed by real-time PCR.  
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Supplement Material
Supplement Methods
Computer-based search for putative PPRE in PPAR-gamma promoter. To identify putative PPAR-
responsive elements (PPREs) in the PPAR-gamma promoter, internet-based (http://rulai.cshl.edu/cgi-
bin/TRED/tred.cgi?process=home) Transcriptional Regulatory Element Database and Transcription 
Element Search System (http://www.cbil.upenn.edu/cgi-bin/tess/tess) were applied to search for the 
motif in the 2,000 bps of mouse and human PPAR-gamma promoter by PPAR algorithm (JASPAR 
MA0066)1 as we described previously2.
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Figure II. CCR2 gene and protein expression levels in WT(■) and Mal1-/-(□) peritoneal 
macrophages. 
Blood monocytes were isolated from Mal1-/-/apoE-/-(n=5) and apoE-/-(n=5) mice fed the Western 
diet for more than two weeks. CCR2 gene and protein expression levels were analyzed by real-
time PCR and by FACS. Note ApoE-/- macrophages expressed higher levels of CCR2 gene (A) and 
protein (B,C). CCR2 protein expression levels in unstained (gray line) or stained apoE-/- monocytes
(filled with gray color) versus Mal1-/-/apoE-/- cells (bold black line). Graphs represent data (Mean 
± SEM; *p<0.05 between these groups). 
CB
Figure III. Identification of a putative PPARγ responsive element (PPRE) in the mouse and 
human PPAR-gamma genes.
A: A computer-based program search yielded three candidate sequences from low to high probability 
score (0.14 to 4.09 at a cutoff score of 0). We further analyzed these sequences by comparing the 
conservation between the human and mouse species and by comparing with consensus PPRE and 
known functional PPREs in PPAR-gamma target genes. We found the site with the highest score
Supplement Material
(AGGGCAAAGGCCT) is located between -917 to -905 in mouse PPAR-gamma promoter 
(NM_011146) and -841 to -829 in human PPAR-gamma promoter (NM_005037) and it is 
100% conserved between human and mouse and has 10/13 (76.9%) of identity with 
consensus PPRE sequence. The identified putative PPRE is bold and underlined in the 
mouse and human PPAR-gamma promoters. Comparison of conservation of the putative 
PPRE between mouse and human species is 100%. 
B:   Comparison of the putative PPRE with consensus and known PPREs in PPAR-gamma target 
genes reveals high similarity with known functional PPREs in PPAR-gamma target genes. 
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